James Davis

Florida

Freelance Writer and Editor at Freelance

Religion reporter for Sun Sentinel, Ft. Lauderdale; evangelical Christian, jazz-fusion diehard, digital photography enthusiast, Lord of the Rings geek.

Featured in: Favicon

usatoday.com Favicon

bandcamp.com Favicon

nydailynews.com Favicon

fortune.com Favicon

marketwatch.com Favicon

politico.com + 68 more

Articles

Development of an Endothelial Activation and Stress Index (EASIX)-based predictive model for cytokine release syndrome and neurotoxicity after B-cell maturation antigen directed chimeric antigen receptor T-cell therapy for relapsed/refractory multiple mye

2 weeks ago | nature.com | Utkarsh Goel |James Davis |William Wesson |Sandra Mazzoni |Mikhaila Rice |Faiz Anwer

The Endothelial Activation and Stress Index (EASIX) score [lactate dehydrogenase (LDH) (U/L) x creatinine (Cr) (mg/dL)/platelet count (109/L)] is a marker of endothelial dysfunction and was initially developed to predict overall survival (OS) after allogeneic hematopoietic cell transplantation [1].
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma - Blood Cancer Journal

2 months ago | nature.com | James Davis |Mikhaila Rice |Kelley Julian |Charlotte Wagner |Shebli Atrash |Jack Khouri | +1 more

TO THE EDITOR:Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by the activation of T-cells and is commonly seen in patients receiving immune effector cell therapies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) which target varying tumor antigens such as CD19, CD20, B-cell maturation antigen (BCMA), or GPRC5D depending on the type of malignancy.
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - Blood Cancer Journal

Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more

AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - Blood Cancer Journal

Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more

AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
Representation of Native Hawaiian and Pacific Islander Individuals in Clinical Trials

Oct 29, 2024 | jamanetwork.com | Deborah A. Taira |Brendan Seto |James Davis |Mona Shing Ranken

Key PointsQuestion Is the proportion of Native Hawaiian and Pacific Islander participants in clinical trials for the 10 drug products with top worldwide sales forecasts in 2024 different from the proportion of Native Hawaiian and Pacific Islander individuals in the US population?
Redefining Data-Centric Design: A New Approach with a Domain Model and Core Data Ontology for Computational Systems

Sep 2, 2024 | preprints.org | William Johnson |James Davis |Tara Kelly

Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 2 September 2024 / Approved: 2 September 2024 / Online: 2 September 2024 (08:53:49 CEST) Johnson, W.; Davis, J.; Kelly, T. Redefining Data-Centric Design: A New Approach with a Domain Model and Core Data Ontology for Computational Systems. Preprints 2024, 2024090037. https://doi.org/10.20944/preprints202409.0037.v1 Johnson, W.; Davis, J.; Kelly, T.
Redefining Data-Centric Design: A New Approach with a Domain Model and Core Data Ontology for Computational Systems

Sep 1, 2024 | arxiv.org | James Davis |Tara Kelly

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Safety and efficacy of B cell maturation antigen‐directed CAR T‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis

Aug 27, 2024 | onlinelibrary.wiley.com | Utkarsh Goel |Danai Dima |James Davis |Nausheen Ahmed

What is the new aspect of your work? This multicenter retrospective study represents the largest case series describing the use of standard of care chimeric antigen receptor (CAR) T-cell therapy in patients with AL amyloidosis and concurrent relapsed/refractory multiple myeloma. What is the central finding of your work?
Lifelong learning and professional development in software engineering

May 10, 2024 | davisjam.medium.com | James Davis

I am on the faculty of Electrical & Computer Engineering at Purdue University, where I research and teach coursework in software engineering. I was formerly a software engineer (QA) at IBM. Sometimes students ask me the following question: " How do I stay up-to-date in software engineering? "Here are my thoughts on the topic. Because it's the right thing to doIn case you're not aware, the two primary professional societies for the computing profession are the ACM and the IEEE .
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium - Blood Cancer Journal

Apr 11, 2024 | nature.com | Aimaz Afrough |Doris Hansen |Surbhi Sidana |Lauren C. Peres |Danai Dima |Joseph McGuirk | +6 more

Idecabtagene vicleucel (ide-cel) the first FDA-approved gene therapy for relapsed refractory multiple myeloma (RRMM). However, its administration presents challenges in logistical management, selecting bridging therapy (BT), and customizing T-cell manufacturing, a complex process spanning several weeks [1]. In the KarMMa trial, BT was allowed but limited to specific prior drug classes (e.g., dexamethasone, cyclophosphamide (Cy), daratumumab, carfilzomib, bortezomib, or pomalidomide) [2].

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 222
Tweets: 378
DMs Open: No

James Davis

James Davis @scribeftl

29 Aug 11

A school headmaster who wears a tie with Daffy, Bugs and Sylvester can’t be all bad. http://t.co/sfHdJmo

James Davis

James Davis @scribeftl

26 Aug 11

The more education you get, the less you attend church, right? Wrong. http://t.co/KbsE6Dt

James Davis

James Davis @scribeftl

26 Aug 11

Is anyone from South Florida planning to go up north for relief work after Hurricane Irene? I’m helping resear… (cont) http://t.co/PZHOyLH